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I, Abstract 
This thesis is part of ongoing research in the structure-activity relationship studies of 
various lavendamycin analogs as possible chemotherapeutic agents. The specific 
work contained in this thesis deals with two very similar analogs of lavendamycin: 
-
7 -N-acetydemethyllavendamycin sec-butyl ester and amide. By synthesizing these 
two similar analogs and eventually testing them for biological activity, a better 
understanding of the effects of structure on activity can be obtained. These 
structure-activity relationship studies are designed to lead to analogs of 
lavendamycin that have a high selective toxicity for rask oncogene transformed cells. 
-
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III. Background Information 
Lavendamycin (1) was first discovered in the fermentation broth of the microorganism 
Streptomyces lavendulae by researchers at Bristol Laboratories in 1981. I Lavendamycin was 
shown to be quite similar to the previously discovered compound, streptonigrin (2), in relation to 
their biological activities and structure. Both lavendamycin and streptonigrin have been shown to 
exhibit potent antitumor activity, but have been unusable thus far due to their high degree of 
cytotoxicity. 2. 3. 4 Lavendamycin also exhibits low water solubility, which makes it even less 
suitable for clinical applications. I 
o 
o 
Several mechanisms have been proposed for the cytotoxicity of streptonigrin and other 
quinones. DNA cleavage has been one observed result of quinones, which is believed to be 
correlated to the quinone reduction potential. 5 Other mechanisms have dealt with the effects of 
the compounds on the electron transport system within the mitochondria. 6- lo However, no single 
mechanism has fully elucidated the effects of these compounds as cytotoxic agents. 
Streptonigrin has much greater cytotoxic and antitumor activity than many quinoline-5,8-
diones that have been tested 7 Preliminary studies by our research group have shown that 
--
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lavendamycins are more potent than their smaller quinolinedione analogs (the A-B ring portion of 
lavendamycin). While lavendamycin has been shown to be less potent than its counterpart 
streptonigrin, it has exhibited promising antitumor activities against ~K oncogenic tumors.1L 12 
Until recently, efficient methods of preparing lavendamycin analogs have been nonexistent. 
After the discovery of lavendamycin in 1981, several research groups started to work on methods 
to synthesize the entire pentacylic structure of lavendamycin. The first published synthesis of 
lavendamycin methyl ester originated from the work of Kende et at at the University of 
Rochester. 13, 14 Their method involved a condensation to acquire the A-B ring portion and 
Bischler-Napieralski cyclodehydration to produce the complete, pentacyclic product. Other 
methods evolved through the years, one of which involved a Pictet-Spengler condensation to add 
j3-methyl tryptophan and a quinoline analog to form the main skeleton ofthe compound. 1s 
In 1993, Behforouz's group at Ball State University reported a short and practical 
synthesis oflavendamycin methyl ester, using a novel azadiene Diels-Alder reaction followed by a 
condensation. 16 This synthesis consisted offive steps with an overall yield of33%. Recently, 
Behforouz's group has introduced another five step synthesis to increase the overall yield to 
nearly 40%.11, 17 
Behforouz's research group has been using this efficient synthesis for several years now, 
producing many analogs of the antitumor agent lavendamycin. Structure-activity relationship 
studies have been ongoing by Behforouz's group. These studies are focused upon finding the 
relationship betwe1en structure and the biological activity of the compounds. 
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IV. Synthesis of Lavendamycin Analogs 
Since its discovery in 1981, lavendamycin has been synthesized by several research 
groups. In 1984, Kende and Ebetino at the University of Rochester reported the synthesis of 
lavendamycin methyl ester using a Friedlander condensation to produce the A-B ring portion and 
a Bischler-Napierski cyc1odehydration to make the final pentacyc1ic product. 13 In addition, they 
reported using 13-methyl tryptophan as an intermediate in their condensation. Next, Hibino's 
research group reported the synthesis oflavendamycin methyl ester in 1985. 15 They reported the 
use of a Pictet-Spengler condensation between J3-methyl tryptophan and a quinoline analog to 
produce apentacyc1ic intermediate, which was functionalized to the final product by a series of 
transformations. In 1985, Boger's group reported a total synthesis also, involving twenty steps 
with an overall yield of less than 1%.18 
In 1993, Behforouz's group reported a highly concise synthesis oflavendamycin methyl 
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ester (7), which involved five steps and an overall yield of33% (see 1993 Procedural Scheme).16 
In comparison to previously reported syntheses, Behforouz's method is much more practical in 
terms of number of intermediates, intermediate stabilities, and overall yield. This synthesis 
involved the use of a Diels-Alder condensation of bromo quinone 1 and a novel 1-azadiene 2 to 
make the AB ring portion 3. After oxidizing the methyl group of the quinolinedione to an 
aldehyde 4, a Pich~t-Spengler condensation with ~-methyl tryptophan (5) was performed to 
produce 7-N-acetyllavendamycin methyl ester (6), which was hydrolyzed to produce the final 
compound 7. 
7 
In 1996, Behforouz's group reported an even more concise method of producing 
lavendamycin methyl ester. 17 This method has an overall yield of 40% and uses 8-
hydroxyquinoline as a starting material for the synthesis of the A-B ring portion oflavendamycin 
(see Scheme 1). This improved method is, in fact, the one utilized in this thesis for the synthesis of 
two lavendamycin analogs. 
V. Biological Activity 
Structure-activity relationship studies on lavendamycin and a variety of analogs have been 
ongoing by Behforouz's group for several years. This has only been possible because of concise 
methods to produee lavendamycin and its analogs in good overall yields. Several analogs of 
lavendamycin have: been found to be biologically active, including 7, 8,9, and 10 with 3,9, 18, 
and l30 fold activity against JMK oncogene transformed cells (see table below). 12 These biological 
results have been provided by the National Institute of Health, Eli Lilly, and several other 
--
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collaborators. So far, the SAR studies have shown that the acetamido group at the C-7 position is 
required for the most selective toxicity. In addition, amide and ester functional groups at the C-2' 
position have proven to contribute a great deal of biological activity to the compounds. Thus, the 
purpose of this thesis was to synthesize two analogs, both with the C-7 acetamido group and 
either an ester or an amide group at the C-2' position. By synthesizing these two 
o 
4 
R'NH' 
Analog R1 R2 R3 
7 H C02CH3 CH3 8 CH3CO C02CH3 CH3 9 CH3CO C02(CH2)2CH(CH3)2 H 
10 CH CO H 3 C02CaH17 - n 
These four analogs have 
shown promising antitumor 
activity against cncogene-
transformed cell lines 
NRK K/1 H/1.2 N/4.2 
.1 .031 .11 .06 
.9 .10 .70 N.T. 
1.62 .09 1.42 1.50 
>33 .25 7.60 9.00 
3LL 
.25 
>33 
1.69 
>33 
analogs and obtaining their antitumor activity data against various oncogene-transformed cell 
lines, we will be able to elucidate the roles that the ester and amide functional groups at the C-2' 
position play in relation to activity. Also, a comparison between these compounds and other 
ester/amide containing analogs should help provide additional data on the role of the residue 
group (such as sec-butyl) in relation to activity. 
-
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VI. Total Synthesis 
The Pictet-Spengler condensation of a quinolinedione aldehyde and a tryptophan results in 
the final pentacyclic lavendamycin derivative. The quinoline aldehyde is fully functionalized prior 
to the condensation, as is the tryptophan. The solvent used for each condensation was carefully 
purified and dried prior to use, as were all reactants. The Pictet-Spengler condensation is believed 
to proceed through a spiroindolenine intermediate. 19 
The quinoline aldehyde was prepared in the following manner (refer to Scheme 1). 8-
hydroxy-2-methylquinoline (1) was purchased from Aldrich, and a nitration yielded a dinitro 
product 2. The nitration is performed with a concentrated nitric and sulfuric acid mixture. Since 
the hydroxyl group of 8-hydroxy-2-methylquinoline is an ortho-para director, the nitro groups 
are added accordingly. This reaction is quite exothermic, so an ice bath was used to keep the 
reaction temperature below 50° c. 
Scheme 1 
yo HN03 ~ N 'CH3 H2N03 
OH 1 
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H21 Pd-C 5% 
.. W ~ /. 02N N CH3 conc HCI 
OH 2 
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.. 
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~ ACNH¥N~CH3 
OAC 3 
o 
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Next, the dinitro 2 was reduced to give the ammonium chloride salt. This reaction was 
performed using a Parr hydrogenator and 43 psi for 24 hours; HCI was placed in the 
hydrogenation mixture to change the reduced amino groups to ammonium chloride salts. This was 
necessary to help protect the resulting amino compound from oxidation (it is susceptible to air 
due to the electron contributing nature of the amino groups on the aromatic ring). The ammonium 
chloride salt was not isolated, but immediately placed into solution with sodium acetate, a base, 
and sodium sulfite, an antioxidant. The patient addition of acetic anhydride over time afforded the 
diacetamido product 3. This reaction can be explained by the nucleophilic attack of the amino 
groups on the carbonyl carbons of acetic anhydride. 
The diacetamido compound 3 was then oxidized with potassium dichromate, in a solution 
of glacial acetic add, to yield the quinolinedione 4. An extraction of the aqueous reaction mixture 
with dichloromethane was performed, and the organic solution was neutralized with 5% NaHC03. 
Rotary evaporation of the organic extracts afforded the yellow product. 
7-Acetamido-2-methylquinoline-5,8-dione (4) was then oxidized with selenium dioxide in 
a wet dioxane solution. This reaction required nearly 24 hours under an argon environment. The 
selenium dioxide and water react to form a reactive oxide of selenium, which serves to oxidize 
only the methyl group of the dione to an aldehyde. This quinoline aldehyde 5 was used to 
synthesize both analogs described in this thesis, and was produced with 17% yield overall. 
The preparation of tryptophan sec-butyl ester (7) was performed in the following manner 
(refer to Scheme 2). (L)-Tryptophan (6), purchased from Aldrich, was refluxed with sec-butyl 
alcohol and a small amount of dry HCI for a period of 22 hours. This esterification afforded the 
--
-
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final tryptophan sec-butyl ester (7). Compound 7 was used in the Pictet-Spengler condensation, 
along with the quinoline aldehyde 5, to produce 7 -N-acetyldemethyllavendamycin sec-butyl ester 
(8) with approximately 7% yield overall. 
The preparation of tryptophan sec-butyl amide (12) was performed in the following 
manner (see Scheme 3). N-Cbz tryptophan (9), purchased from Aldrich, was reacted with N-
hydroxysuccinimide in the presence of dicydohexylcarbodiimide. This mixture was cooled and 
Scheme 2 
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stirred for two hours to afford the Cbz tryptophan succinimide ester (10). This compound was 
then mixed with a small amount of sec-butyl amine to replace the ester bond with an amide. This 
-12 
reaction resulted in the formation of Cbz tryptophan sec-butyl amide (11) Next, the Cbz 
(carbobenzyloxy) protecting group was cleaved off using ammonium formate in the presence of 
10% palladium on charcoal in methanol This reaction resulted in the final tryptophan sec-butyl 
amide (12), Compound 12 was used in the Pictet-Spengler condensation, along with the quinoline 
aldehyde 5, to produce 7-N-acetyldemethyllavendamycin sec-butyl amide (13), 
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VII. Expe'rimental 
A. General Information 
Reagents: 8-hydroxy-2-methylquinoline, selenium dioxide, L-Tryptophan, N-
carbobenzyloxytryptophan, N-hydroxysuccinimide, and N-dicyclohexy1carbodiimide were 
purchased from the Aldrich Chemical Company. 
13 
Solvents: All solvents used were reagent grade (except for 1,4-dioxane, xylene, and anisole, 
which were dried before use, see below) 
Melting Points: 
NMR Spectra: 
All melting points were determined using a Thomas-Hoover capillary 
melting point apparatus and are uncorrected. 
IH NMR Spectra were recorded on a Varian Gemini 200 Spectrometer 
in CDCl3 using TMS as an internal standard. 
Low and High R.esolution Mass Spectra: EI and F AB Mass Spectra were obtained at the 
Chemistry Department of the University of Illinois. 
Thin-Layer Chromatography: 
B. Solvent Purification 
Eastman silica gel strips with fluorescent indicator were 
used to determine purity for all products. 
Xylene and anisole, the solvents used for the two condensation reactions, were carefully 
dried and purified. This involved refluxing the solvents with sodium spheres for 1-2 hours (or until 
the spheres appeared metallic), and then placing benzophenone in the reflux mixture. A blue color 
was indicative of dlryness, and then the solvents were distilled. 
It was quite necessary to purify and dry 1,4-dioxane prior to use because of its tendency to 
polymerize. To purify the solvent, it was refluxed with a large amount of potassium hydroxide. 
After decanting the solvent, it was dried by refluxing with sodium spheres and benzophenone as 
mentioned previously . 
--
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c. Procedures 
Preparation of 8-,Hydroxy-2-methyl-5,7-dinitroquinoline (2) 
Concentrated nitric (140 mL) and concentrated sulfuric (60 mL) acids were placed in a 
500 mL Erlenrney,er flask and stirred while cooling with an ice bath. To this acid mixture, 8-
hydroxyquinoline (1; 20.00 g, 0.125 mol) was carefully added in small portions over a period of 
45 minutes while keeping the mixture between 20-30°C. When the addition was complete, the 
reaction was left to stir at room temperature for 3 hours. Next, the reaction mixture was poured 
into a 2L beaker containing 800mL of ice water to produce a yellow precipitate instantly. The 
solid was filtered off, washed with water and diethyl ether to give 20.20g (64%) of product 2. mp. 
293-296°C. IH NMR (CDCI3): b 9.65 (IH, d, J=9.1Hz, C-4H), 9.20 (lH, s, C-6H), 8.13 (lH, d, 
J=9.1Hz, C-3H), 2.93 (3H, S, C-2CH3)' 
Preparation of 5,7-Diacetamido-2-methyl-8-acetoxyquinoline (3) 
To a thick·walled 500 mL hydrogenation flask, finely ground 8-hydroxy-2-methyl-5,7-
dinitroquinoline (2:; 6.00 g, .024 mol) was added along with 13 mL of concentrated hydrochloric 
acid, 120 mL water, and 2.2 g 5% palladium-on-charcoal. The flask was quickly placed on a Parr 
hydrogenator and hydrogenated overnight, starting at 41 psi and falling to 30 psi. The next day, 
the reddish mixture was removed from the hydrogenator and filtered to remove the palladium-on-
charcoal, which was rinsed with water (30 mL x 2). Moving quickly, 6 g of Na2 S03, 8 g of 
NaOAC, and a magnetic stir bar were added to the dark red filtrate; this solution was cooled and 
stirred vigorously while 90 mL of acetic anhydride was added dropwise. Once the addition was 
complete, the precipitate was filtered to give a whitish solid. Next, the filtrate was rotary-
evaporated to 115 of its original volume, and another 25 mL of acetic anhydride was added. The 
resulting precipitate was filtered again, and the two precipitates were rinsed with water, combined 
and dried to give 5 .87 g of product 3 (77%). 
--
-
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Preparation of 7-Acetamido-2-methylquinoline-5,8-dione (4) 
Using a 500 mL Erlenmeyer flask containing a magnetic stir bar, 5,7-diacetamido-2-
methyl-8-acetoxyquinoline (3) (2.73 g, .0087 mol) and 120 mL glacial acetic acid were mixed. 
Next, 8.8 g (.03 mol) of potassium dichromate was added and the mixture was stirred at room 
temperature for 24 hours. The reaction mixture was then added to a 2L separatory funnel 
containing 900 mL water, and extracted with dichloromethane (250 mL x 4). The combined 
organic extracts were concentrated by rotary-evaporation to nearly 200 mL, and then washed 
with 5% sodium hlcarbonate (to pR 7). After drying over magnesium sulfate, the concentrated 
extracts were then rotary-evaporated to yield 2.01 g (51%) of yellow solid 4. mp. 216-219°C. lR 
NMR (CDCI3): 08.41 (lR, s, C-NH), 8.32 (lR, d, J=8.1Hz, C-4H), 7.92 (lR, s, C-6H), 7.57 
(lR, d, J=8.1Hz, C-3H), 2.78 (3R, s, C-2 CH3)' 2.33 (3R, S, NHCOCH3)' 
Preparation of 7-Acetamido-2-formylquinoline-5,8-dione (5) 
To a 100 mL round-bottomed flask equipped with a magnetic bar and argon flow, 7-
acetamido-2-methylquinoline-5,8-dione (4; 1.15 g, 4.7 mmol), 1.08 g selenium dioxide, 17.5 mL 
of purified and dried dioxane, and 0.625 mL water were added. The mixture was slowly heated in 
an oil bath until constant reflux was achieved, and then refluxed for 20 hours. After determining 
that the reaction was completed using TLC (50/50 CRCl3 : EtOAC), an additional 15 mL of 
dioxane was added and refluxing was maintained for another 15 minutes. Next, the mixture was 
vacuum filtered while hot, and the selenium metal precipitate was washed with 25 mL of 
dichloromethane. The filtrate (containing product) was saved, and the selenium metal precipitate 
was placed in a beaker and thoroughly mixed with 50 mL dichloromethane while heating to a boil. 
This mixture was once again filtered, and the filtrates were combined and rotary-evaporated to 
yield a brown precipitate. After two days of vacuum drying, the solid was found to be 0.84 g 
(69%). mp 220-223°C. lR NMR (CDCI3 ): 0 10.31 (lR, s, ArCHO), 8.64 (lR, d, J=7.7Hz, C-
48),8.07 (lR, s, C-6H), 8.34 (lR, d, J=7.7Hz, C-38), 8.46 (lR, s, C-7NH), 2.37 (3R, s, 
COCH3). 
--
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Preparation of Tryptophan sec-butyl ester (7) 
L-Tryptophan (6; 1 g, 4.9 mmol) and 60 mL of sec-butyl alcohol were placed in a 100 mL 
round-bottomed flask equipped with a magnetic stirring bar, water condenser and an oil bubbler. 
The flask was cooled in an ice bath for several minutes, and then 12 mL of dry HCl-ether solution 
was added into the flask using a syringe through a rubber septum. The ice bath was then removed 
and replaced by an oil bath, and the mixture was heated to 120°C and left to reflux for 22 hours 
while stirring vigorously. Next, 3 drops of concentrated sulfuric acid was added, and the mixture 
was refluxed for an additional two hours. TLC was used to determine the completion (100% 
EtOAC) of the reaction and the mixture was cooled and rotary-evaporated to dryness. The 
resulting solid was dissolved in 50 mL of dichloromethane, and then washed with 5% sodium 
bicarbonate until pH~ 8. This solution was extracted with dichloromethane (40 mL x 4), washed 
with brine, and dried over magnesium sulfate. Rotary-evaporation gave 0.88 g (69%) ofa light 
brown gel (7). IH NMR (CDCI3 ): 88.22 (IH, br s, -NB), 7.65 (lH, d, J=7.7Hz, C-4H), 7.25-7.1 
(2H, m, C-5 and C-6H), 7.35 (IH, d, J=7.7Hz, C-7H), 7.05 (lH, s, C-2H), 3.87-3.75 (lH, m, 
RCOOCHR2), 1.3 (2H, d, J=6.9Hz, RCH2R), .85 (3H, t, J=7.1Hz, CH2CH3), 1.22-1.15 (2H, m, 
RCHCH2CH3), .90 (3H, d, J=7.3Hz, CHCH3). 
Preparatioo of 7-N-Acetyldemethyllavendamycin sec-butyl ester (8) 
L-Tryptophan sec-butyl ester (7; 0.2568 g, l.0 mmol) was dissolved in 12 mL of freshly 
distilled xylene and stored under argon in a closed container. To a 250 mL round-bottomed flask 
equipped for argon flow and a magnetic stirring bar, 7-acetamido-2-formylquinoline-5,8-dione (5; 
0.2401 g) and 145 mL offreshly distilled xylene were placed and heated to lOO°e. The 15 mL 
tryptophan/xylene solution was then added to the flask using a syringe. This mixture was then 
heated to 130°C and left to stir for 16 hours. After using TLC to determine the reaction's 
completion (CH2CI2 : MeOH, 2: 1), the mixture was filtered to reveal a green precipitate. The 
filtrate was left in the refrigerator overnight and the next day more precipitate was obtained by 
filtration. These precipitates were combined to give 0.2785 g (57%) of product. The precipitate 
.-
-
17 
was recrystallized in dimethyl sulfoxide to yield the pure product 8. mp 268°C. IH NMR (CDCl3 
): 0 11.86 (1H, br s, -NH), 9.27 (1H, d, J=8.4Hz, C-4H), 8.97 (1H, s, C-6H), 8.61 (1H, d, 
J=8.3Hz, C-3H), 8.47 (IH, br s, C-7NH), 8.29 (1H, d, J=8.1Hz, C-9'H), 8.03 (1H, s, C-3'H), 
7.77-7.71 (2H, m, C-lO'H and C-ll'H), 7.40 (1H, d, J=9.7Hz, C-12'H), 5.35-5.20 (IH, m, 
COOCHR2), 2.38 (3H, s, CH3CONH), 1.50-1.44 (2H, m, RCH2CH3), 1.26 (3H, s, R2CHCH3), 
1.10 (3H, t, J=7.3Hz, RCH2CH3). FAB-MS, mlz (relative intensity), 485.2 (24.75), 309.0 
(17.73), 155.1 (57.69), 119.0 (100); HRMS mle for C27H2SN40S: calculated 485.182495, found 
485.182300. 
Preparation of Benzyloxycarhonyltryptophan succinimide ester (to) 
This procedure is similar to the method used by Tolstikov. 20 
To a 100 rnL round-bottomed flask with a magnetic stirring bar, N-
carbobenzyloxytryptophan (1.706 g, 5 mmol), 0.598 g (5.2 mmol) N-hydroxysuccinimide, and 50 
mL of purified, dry dioxane were added. This mixture was stirred until it became homogenous, 
and then cooled to nearly 12°C in an ice bath. Dicyc1ohexylcarbodiimide (1.04 g, 5 mmol) was 
added, and the ice bath was changed to a cold water bath. The reaction mixture was allowed to 
stir for 2 hours while maintaining a temperature of 15-20°C. The water bath was then removed 
and the mixture was stirred for an additional two hours. After the completion of the reaction 
(TLC 2.5 mL EtOAc : 1.5mL hexane), the precipitate was filtered and the white solid was washed 
with a small amount of dioxane. The filtrate was rotary-evaporated to obtain a clear gel. The gel 
was placed under vacuum with heat (40°C) for several days to obtain 1.81 g (82%) of a white 
solid product (10). IH NMR (CDCI3): 08.25 (1H, br s, N-H), 7.55 (1H, d, J=5.76Hz, C--4H), 
7.36 (1H, d, J=6.80Hz, C-7H), 7.27 (2H, d, C-5 and C-6H), 7.07 (IH, s, C-2H), 5.30 (1H, br s, 
CONH), 5.12 (2H, s, benzyl-CH2-R), 3.76 (1H, m, NH-CH-R), 3.50-3.43 (2H, m, C-4' CH2)' 
---
Preparation of Btmzlyoxycarbonyltryptophan sec-butyl amide (11) 
This procedure is similar to the method used by Tolstikov?O 
18 
To a 100 mL round-bottomed flask equipped for an argon flow and a magnetic stirring 
bar, benzyloxycarbonyltryptophan succinimide ester (10; 0.870 g, 2 mmol), 0.22 mL (2 mmol) of 
sec-butyl amine, 0.28 mL of purified triethylamine, 26 mL of absolute ethanol, and 24 mL of 
chloroform were placed. The reaction mixture was stirred at room temperature for two hours 
while monitoring the reaction's progress with TLC (1 mL EtOAc : 2 mL CHCI3). Once 
completed, the mixture was rotary-evaporated to a clear gel. This gel was dissolved in 60 mL 
EtOAc and washed with 30 mL of water. Next, the solution was washed with 10% citric acid (25 
mL x 2) and then with 12 mL of 1. 2M NaHC03 . The organic solution was then dried over sodium 
sulfate and rotary-evaporated to obtain a clear, brown gel. After two days under vacuum, 0.615 g 
(78%) ofa white product 11 was obtained. IH NMR (CDCI3): 88.1 (lH, br s, N-H), 7.71 (lH, 
d, J=5.86Hz, C--4H), 7.30 (1H, d, J=6.56Hz, C-7H), 7.27 (2H, dd, C-5 and C-6H), 7.03 (1H, s, 
C-2H), 5.5 (lH, br s, CONH), 5.30 (1H, d, CONH), 5.12 (2H, s, benzyl-CH2-R), 4.43 (lH, t, 
J=5.5Hz, C-5'H), 3.76 (1H, m, NH-CH-R), 3.40-3.13 (2H, m, C-4' CH2), 1.24 (2H, t, J=7.98Hz, 
-CH(CH3)CH2CH j ), .9 (3H, d, J=6.42, -CH(CH3)CH2CH3), .79 (3H, t, J=6.60, 
CH(CH3)CH2CH3)· 
Preparation of Tlryptophan sec-butyl amide (12) 
This procedure is similar to the method used by Tolstikov. 20 
A magnetie stirring bar and 0.5 g (1.3 mmol) ofbenzyloxycarbonyltryptophan sec-butyl 
amide (11) were placed in a 100 mL round-bottomed flask equipped for argon flow, along with 
30 mL of dried methanol. To this mixture, 0.26 g (5.5 mmol) of dried ammonium formate and 
0.26 g of 10% palladium on charcoal was added and the mixture was left to stir for 30 minutes 
under argon while monitoring with TLC (l EtOAc : 2 CHCI3). Once completed, the reaction 
mixture was filtered and the filter cake was washed with 10 mL of methanol. The filtrate was then 
rotary-evaporated until nearly dry, and then the water bath temperature was raised to 100°C to 
obtain a brownish precipitate. This precipitate was dried under vacuum in a 60°C oil bath for two 
days to obtain 0.26 g (75%) of white solid product 12. IH NMR (CDCI3): 88.32 (IH, br s, N-
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B), 7.71 (tH, d, J=7.22Hz, C-4B), 7.12 (tH, d, J=8.44Hz, C-7B), 7.27 (2H, dd, C-5 and C-6H), 
7.01 (IH, s, C-2H), 3.90 (IH, t, J=6.5Hz, C-5'B), 3.72-3.68 (tH, m ,CB(CH3)CH2CH3 ), 3.45-
2.90 (2H, m, C-4' CB2), 1.39 (2H, m, -CH(CH3)CB2CH3), 1.09 (3H, d, J=6.5, -
CH(CB3)CH2CH3), .90 (3H, t, J=6.75, -CH(CH3)CH2CH3). 
Preparation of 7-·N-Acetyldemethyllavendamycin sec-butyl amide (13) 
For this procedure a 250 mL round-bottomed flask, flowing argon, a magnetic stirring bar, 
and a Dean-Stark collector were used. 7-acetamido-2-formylquinoline-5,8-dione (5; 109 mg, 
0.45 mmol) and tryptophan sec-butyl amide (12; 116.4 mg, 0.45 mmol) were placed in the flask, 
along with 180 mL of dried anisole. This mixture was stirred and heated, using an oil bath, to 
167°C over a period of two hours. The solution was refluxed for a total of 15 hours, and the 
completion of the reaction was verified by TLC (5% MeOH in CHCI3). The mixture was filtered 
while hot to remove some brown solid impurity. The filtrate was rotary evaporated to dryness, 
and the resulting solid was dissolved in a minimal amount of CHCl3 and acetone. This solution 
was set aside overnight at room temperature, and the following day filtration yielded 73 mg 
(35%) of orange product 13. mp 306-308°C. IH NMR (CDCI3): 0 11.80 (tH, br s, NH), 9.10 
(tH, s, C-3'H), 9.00 (IH, d, J=8.4Hz, C-4B), 8.63 (tH, d, J=8.4Hz, C-3H), 8.49 (tH, br s, C-
7NH), 8.28 (tH, d, J=7.7Hz, C-ll'B), 8.04 (tH, s, C-6B), 7.95-7.89 (tH, m, CONH-see-butyl), 
7.77-7.69 (2H, m, C-I0'H and C-11'B), 7.41 (tH, d, J=8.3Hz, C-12'H), 2.39 (3H, s, 
NHCOCB3), 4.25-4.18 (tH, m, NHCH(CH3)CH2CH3), 1.75-1.73 (2H, m, 
NHCH(CH3)CB2CH3), 1.39 (3H, d, J=6.56, NHCH(CB3)CH2CH3), 1.07 (3H, t, J=7.44Hz, 
NHCH(CH3)CH2CB3)· 
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Appendix B - Research Presentations 
The author of this thesis presented the work within these pages on two different 
occasions: once for the Ball State Chemistry Department, and once at the Butler University 
Undergraduate Research Conference on April 11, 1997. These presentations have served to help 
the author in the overall understanding of this project, as well as to aid Dr. Mohammad Behforouz 
in his ongoing studies. 
-. 
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